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Abstract
Background: The Baby-OSCAR trial is a multi-centre, randomised, placebo-controlled parallel group trial of early
treatment of large patent ductus arteriosus (PDA) with ibuprofen in extremely preterm infants. This paper describes
the statistical analysis plan for the short-term health outcomes of the Baby-OSCAR trial.
Methods and design: This is a randomised controlled trial to determine if early-targeted treatment of a large PDA
with parenteral ibuprofen in extremely preterm babies improves short and long-term health and economic
outcomes. Infants born between 23+0 and 28+6 weeks of gestation, confirmed by echocardiography as having a
large PDA (with a diameter of at least 1.5 mm and unrestricted pulsatile PDA flow pattern), with parental informed
consent, were randomly allocated to receive either ibuprofen or placebo within 72 h of birth. The primary outcome
is a composite of death by 36 weeks’ postmenstrual age or moderate or severe bronchopulmonary dysplasia (BPD)
at 36 weeks’ postmenstrual age.
Results: Baseline demographic and clinical characteristics will be described by randomised group. The primary
analysis will be on the modified intention to treat (ITT) population. Counts and percentages will be presented for
binary and categorical variables, and mean and standard deviation or median and interquartile range will be
presented for continuous variables. For binary outcomes, risk ratios and confidence intervals will be calculated using
log binomial or Poisson regression with a robust variance estimator. Continuous outcomes will be analysed using
linear regression models, or quantile regression models if skewed. Analyses will be adjusted for all minimisation
factors where technically possible, and correlation between siblings from multiple births will be accounted for by
nesting the clusters as a random effect. Both crude and adjusted effect estimates will be presented, with the
primary inference based on the adjusted estimates. Ninety-five per cent confidence intervals will be used for all pre-
specified outcome comparisons.
Conclusion: This paper describes the statistical analysis plan for short-term health outcomes of the trial, including
the analysis principles, definitions of important outcomes, methods for primary analysis, pre-specified subgroup
analysis, and secondary analysis. The plan was finalised prior to completion of short-term follow-up.
Trial registration: ISRCTN registry ISRCTN84264977. Registered on 15 September 2010.
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Introduction
This paper details the proposed presentation and ana-
lyses for the main paper(s) reporting results from the
National Institute for Health Research (NIHR) Health
Technology Assessment (HTA) programme funded mul-
ticentre randomised controlled trial of early treatment
for closure of large Patent Ductus Arteriosus (PDA) with
ibuprofen in extremely preterm infants (Baby-OSCAR).
Baby-OSCAR is a randomised controlled trial to deter-
mine short- and long-term health and economic out-
comes of the treatment of a large PDA in extremely
preterm babies with ibuprofen within 72 h of birth. In-
fants who were born between 23+0 and 28+6 weeks of
gestation, confirmed by echocardiography as having a
large PDA, were randomised to receive either ibuprofen
or placebo within 72 h of birth. The primary outcome is
a composite of death by 36 weeks of postmenstrual age,
or moderate or severe bronchopulmonary dysplasia
(BPD) at 36 weeks of postmenstrual age [1].
This paper describes the statistical analysis plan for
the short-term outcomes of the main trial, including the
analysis principles, definitions of outcomes, methods for
primary analysis, pre-specified subgroup analysis, and
secondary analysis. The analyses for both the long-term
outcomes at 2 years of age and the health economic
evaluation will be detailed in separate publicly-available
analysis plans.
This statistical analysis plan conforms to the published
guidelines on the content for statistical analysis plans in
clinical trials [2] and was finalised prior to completion of
short-term follow-up to the trial. Any deviations from
this plan will be described and justified in the final re-
port of the trial.
Background information
Rationale
This trial follows an internal pilot phase, which has been
run to assess the suitability of trial procedures and likeli-
hood of recruitment targets being achieved. The trial
aimed to recruit approximately 730 infants in total (in-
cluding those recruited during the internal pilot phase)
from 35 UK tertiary neonatal units (and five for the in-
ternal pilot phase).
PDA is associated with a number of serious and life-
threatening short and long term complications including low
blood pressure (hypotension), bleeding in the lungs (pulmon-
ary haemorrhage) and brain (intraventricular haemorrhage
(IVH)), systemic complications such as necrotising entero-
colitis (NEC), bronchopulmonary dysplasia (BPD), and long
term health problems such as neurodevelopmental disability
and chronic respiratory problems. The persistence of PDA is
associated with an 8-fold rise in neonatal mortality [3]. In
addition, as PDA is very common in extreme preterm babies
and is associated with a prolonged need for respiratory sup-
port and hospitalisation, it places a significant financial bur-
den on the National Health Service (NHS).
Historically, clinicians who have been concerned about
the complications associated with a PDA have attempted to
close PDAs utilising medical (pharmacological) or surgical
treatment. Traditionally, medical treatment is instituted as
prophylactic treatment (within 24 h of birth) or symptom-
atic treatment (usually 5−7 days after birth). Prophylactic
pharmacological treatment of all preterm babies unneces-
sarily exposes a large proportion of babies to the potentially
serious side effects of drug treatment, when their PDA
would have closed spontaneously. Symptomatic treatment
on the contrary delays treatment whilst waiting for symp-
toms to appear and could result in a loss of treatment bene-
fit as irreversible damage may have already been done.
Moreover, the practice of a conservative approach of
not treating seems to originate from uncertainty regard-
ing the management of PDA rather than evidence
favouring no intervention. This is because most studies
conducted to date have involved more mature preterm
babies (over 1000 g or 28 weeks of gestation) whose
PDA is more likely to close spontaneously. The studies
were also largely designed to assess PDA closure rates
rather than clinically important outcomes.
It is now suggested that large PDAs (those with a
diameter of ≥ 1.5 mm) through which blood flow is pul-
satile and unrestricted are less likely to close spontan-
eously. Targeted early treatment of large PDAs whilst
asymptomatic has the potential to overcome the disad-
vantages of both the prophylactic and symptomatic ap-
proaches. Although clinical detection of PDA whilst
asymptomatic is challenging, it can be assessed using
bedside echocardiography.
Non-steroidal anti-inflammatory drugs, especially
indomethacin and ibuprofen have been widely used for
the treatment of PDA. Short-term efficacy of indometh-
acin and ibuprofen are equivalent in the treatment of
PDA [4]. Ibuprofen however appears to reduce the risk
of NEC and is associated with fewer clinical gastrointes-
tinal and renal side effects compared to indomethacin;
hence it is the drug of choice for this trial. Paracetamol
has also been recently reported in case studies for clos-
ure of symptomatic PDA but further research needs to
be done to establish its effectiveness [5].
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The aim of this trial is to examine whether the
pharmacological closure of a large PDA (identified by
echocardiography) in extremely preterm babies whilst
asymptomatic has a clinically important impact on both
short- and long-term health and economic outcomes.
Objectives of the trial
The primary objective of the trial is to determine if se-
lective early treatment of large PDAs (confirmed by
echocardiograph) in extremely preterm babies with ibu-
profen within 72 h of birth reduces the incidence of
death by 36 weeks of postmenstrual age or moderate or
severe bronchopulmonary dysplasia (BPD) at 36 weeks
of postmenstrual age.
The secondary objectives are to determine if the se-
lective treatment of confirmed large PDAs in extremely
preterm babies with ibuprofen within 72 h of birth re-
sults in:
A reduction in the components of the primary
outcome: death by 36 weeks of postmenstrual age;
moderate or severe BPD at 36 weeks of
postmenstrual age, severity of BPD at 36 weeks of
postmenstrual age; other secondary outcomes up to
discharge (see the ‘Secondary short-term outcomes’
section);
Improved health outcomes at 2 years’ corrected age
including survival without moderate or severe
neurodevelopmental disability (long-term primary
objective) and survival without respiratory morbidity
(long-term secondary objective).
An economic evaluation will be carried out from the
perspective of the health service. It will take the form of
a cost-effectiveness analysis presented in terms of cost
per major outcome averted. The major outcomes are
those of the primary outcome, namely death and moder-
ate or severe BPD by 36 weeks of postmenstrual age.
Additional analyses will take place on a range of second-
ary outcomes and on neurodevelopmental outcomes at
2 years. The incremental cost estimate for statistically
significant differences in the pre-specified outcomes in
primary and subgroup analyses would be computed.
Trial design
This is a multicentre, randomised, placebo-controlled
parallel group trial to determine if the treatment of a
large PDA with ibuprofen in extremely preterm babies
(23+0 to 28+6 weeks of gestation) improves short- and
long-term health outcomes and health economic
outcomes.
The main trial was preceded by an internal pilot phase,
which was used to assess the suitability of trial
procedures and likelihood of recruitment targets being
achieved.
The entire trial is anticipated to take 82months to
complete and aims to recruit a total of approximately
730 extremely preterm babies.
Eligibility
Inclusion criteria
Babies will be considered eligible for inclusion into the
trial if they are:
Born at 23+0 to 28+6 weeks of gestation
Less than 72 h old
Confirmed by echocardiography as having a large
PDA which
Is at least 1.5 mm in diameter (determined by
gain optimised colour Doppler), and
Has unrestrictive pulsatile (left to right) flow
(ratio of flow velocity in PDA Maximum (Vmax)
to Minimum (Vmin) > 2:1) or, growing flow
pattern (< 30% right to left), and no clinical
concerns of pulmonary hypertension.
In addition:
The responsible clinician is uncertain about whether
the baby might benefit from treatment to close the
PDA
Written informed consent has been obtained from
the parent(s)
Exclusion criteria
Babies will be excluded from participation in the trial if
they have:
No realistic prospect of survival
Severe congenital anomaly
Clinical or echocardiography suspicion of congenital
structural heart disease that contraindicates
treatment with ibuprofen
Other conditions that would contraindicate the use
of ibuprofen (active bleeding especially intracranial
or gastrointestinal bleeding, coagulopathy,
thrombocytopenia (platelet count < 50,000), renal
failure, life-threatening infection, pulmonary hyper-
tension, known or suspected necrotising enterocoli-
tis (NEC))
Indomethacin, ibuprofen, or paracetamol
administration after birth
Interventions
Ibuprofen will be supplied as a clear sterile solution at a
concentration of 5 mg/ml in ampoules. Cartons contain-
ing four 2-ml single-use ampoules will be provided. Each
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carton will be labelled with a unique code and in com-
pliance with the guidance given in Annexe 13 of the
European Commission’s guidelines for Good Manufac-
turing Practice.
An initial loading dose of 10 mg/kg (2 ml/kg) of ibu-
profen will be administered, followed by two 5-mg/kg (1
ml/kg) doses at 24 and 48 h after the initial dose. Doses
are to be calculated on the birth weight of the baby. If
required, the IMP can be diluted to the appropriate vol-
ume with 5% glucose or 0.9% sodium chloride. Each
dose is to be given as a short intravenous infusion over
15 min. All 3 doses will be given unless there are adverse
effects necessitating stoppage, as referenced in the trial
protocol [1].
Placebo will be supplied as a clear sterile solution of
0.9% sodium chloride for injection. Cartons identical to
those for ibuprofen, each containing four identical
single-use ampoules will be provided. Volume of IMP to
be withdrawn from the ampoule will be calculated fol-
lowing the calculations for ibuprofen dosing.
Following enrolment, the first dose should be adminis-
tered soon after randomisation, after 6 h of age, and
within 72 h of birth. The recommended storage will be
in line with the Summary of Product Characteristics
(SmPC) and once the ampoule is opened the drug must
be used immediately.
Definition of primary and secondary outcomes
Primary outcome
The primary outcome is defined as a composite outcome
of death by 36 weeks of postmenstrual age or moderate
or severe BPD at 36 weeks of postmenstrual age (as de-
fined in Table 1).
The need for oxygen is subjective and hence oxygen
dependency to differentiate mild from moderate BPD
will be confirmed using an ‘oxygen reduction test’. This
is based on the threshold at which the baby is able to
maintain oxygen saturations ≥ 91% whilst breathing in
air or at a given minimum FiO2. Babies unable to main-
tain oxygen saturations ≥ 91% in room air will be con-
sidered to be oxygen dependent and classed as moderate
BPD (oxygen requirements 22–29% or 0.01–1.0 L/min
by low flow nasal cannula). Those babies who can be
weaned to room air and stable will be categorised as
having mild BPD. This test will only apply to those ba-
bies whose oxygen requirements are < 0.3 or low flow
oxygen < 1.1 L/min, and who have not received any add-
itional respiratory support in the previous 24 h. Babies
outside of this will not be tested, but their oxygen re-
quirements will be captured on the relevant case report
form. See Fig. 1 for the oxygen reduction test flow chart.
Secondary short-term outcomes
Due to the multiple number of short-term outcomes
and correlation between some outcomes, statistical infer-
ence will be restricted to a predefined list of outcomes
(see below). Summary statistics by trial arm will be pro-
vided for all other outcomes as indicated below, but stat-
istical inferences (i.e. the calculation of confidence
intervals) will not be made.
Secondary short-term outcomes—statistical inference
provided
Death by 36 weeks’ postmenstrual age
Moderate or severe BPD at 36 weeks’ postmenstrual
age
Incidence or duration of the following up to discharge:
Severe intraventricular haemorrhage (IVH) (grade
III/IV with ventricular dilatation or
intraparenchymal abnormality)
Cystic periventricular leukomalacia (PVL)
Babies treated for retinopathy of prematurity (ROP)
Significant pulmonary haemorrhage (fresh blood in
endotracheal tube with increase in respiratory
support)
Treated for pulmonary hypertension with
pulmonary vasodilator
NEC definitive and/or complicated (Bell stage II and
above) confirmed by radiology and/or
histopathology
Closed or non-significant PDA (< 1.5 mm) at around
3 weeks of age (range of 18–24 days), confirmed by
ECHO (or death, or hospital discharge from recruit-
ing centre, if discharged sooner)
PDA ≥ 1.5 mm at around 3 weeks’ (range of 18–24
days), not treated medically or by surgical closure
Open-label treatment of a symptomatic PDA by
surgical treatment
Discharge home on oxygen
Weight gain: a change in z score between birth and
discharge (or death if sooner)
Secondary short-term outcomes—summarised descriptively
Table 1 Severity-based diagnostic criteria for BPD
Time point of
assessment:
36 weeks of postmenstrual age
Therapy with oxygen > 21% and/or respiratory support for ≥ 28 days
and the following:
Mild BPD Baby is breathing room air
Moderate BPD Baby is in 22–29% oxygen or 0.01–1.0 L/min
Severe BPD FiO2 ≥ 0.3, or low flow oxygen ≥ 1.1 L/min, or
the baby is receiving any respiratory support
(ventilation, CPAP, or high flow oxygen therapy)
to achieve saturations of ≥ 91%
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Severity of BPD at 36 weeks’ postmenstrual age (see




Gastrointestinal bleeding (leading to investigation or
clinical treatment) within 7 days of the first dose of
trial drug administration
Spontaneous intestinal perforation
Medical open-label treatment of a symptomatic
PDA with a COX inhibitor
Administration and duration of inotropic support
Total duration of respiratory support
Invasive ventilation through an endotracheal
tube
Non-invasive support through nasal CPAP, nasal
ventilation, humidified high flow nasal cannula
therapy, or low flow oxygen ≥ 1.1 L/min
Duration of initial hospitalisation (birth to discharge
home)
Postnatal steroid use for chronic lung disease
Tolerance of ibuprofen treatment within the
foreseeable SAE reporting range, described in the
protocol, section 9.1.4
Head circumference: a change in head size z score between
randomisation and discharge (or death if sooner).
Process outcomes
Process outcomes will measure adherence to the proto-
col – see the ‘Protocol non-compliance’ section below
for details.
Fig. 1 Oxygen reduction test flow chart
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Hypothesis framework
This is a superiority trial and all comparisons will be
analysed and presented on this basis.
Sample size and power
Evidence from the TIPP trial suggests that the risk of
death or BPD in extremely low birth weight babies at 36
weeks of postmenstrual age allocated placebo is 52%
(95% confidence interval [CI] 48% to 56%) [6]. However,
this trial investigated the effect of prophylactic treatment
and included all babies weighing 500−999 g. More recent
information using data derived from the latest report of
Neonatal Survey Database from the Trent region [7]
provides an approximate rate of death or BPD by 36
weeks of postmenstrual age of 53% for all babies admit-
ted to the neonatal unit. These babies would have been
treated according to clinical judgement and therefore a
proportion of them would have been treated with ibu-
profen. Given that the risk of death or BPD in babies
with a large PDA is inherently higher, it is estimated that
the risk in this group is 60%.
Su et al [4] compared ibuprofen to indomethacin in
babies of ≤ 28 weeks of gestation having a PDA who
were less than 24 h old. The combined outcome of death
within 30 days or BPD at 36 weeks of postmenstrual age
was observed to be 42% (95% CI 29% to 55%).
It is therefore expected, given that babies will be en-
rolled up to 72 h after birth, that the treatment group in-
cidence of death/BPD at 36 weeks of postmenstrual age
will be approximately 48% in the intervention arm. This
would imply an absolute risk reduction of 12% (60% to
48%) in the primary outcome of the trial for babies ran-
domised to treatment compared to placebo, which is
considered a clinically important difference.
Some babies will require open-label treatment in ei-
ther the treatment or placebo arm. As open-label treat-
ment should be limited to symptomatic babies meeting
only defined criteria, it is considered to have minimal or
no effect on the primary outcome. Thus, adjustment of
the sample size for open-label treatment is not consid-
ered necessary.
Figure 2 depicts a sample size curve for the primary
outcome of the trial of death or BPD by 36 weeks of
postmenstrual age, assuming 90% power, a two-sided 5%
significance level and a 60% control group event rate for
the primary outcome.
Table 2 summarises this information and allows for
1% loss to follow-up in the primary outcome. Minimal
loss to follow-up is expected for the primary outcome
since it is a short-term outcome and recorded whilst the
baby is in hospital.
Thus a sample size of approximately 730 babies in
total (365 per arm) would be required to detect an abso-
lute risk reduction of 12% (power 90%, 2-sided
significance level of 5%) from a control group event rate
of 60% to a treatment group event rate of 48%, assuming
1% lost to follow-up.
n multiple births, the babies are genetically either
identical or very similar, so their outcomes are likely to
be correlated. However, since multiples will be rando-
mised independently, the loss of precision from multi-
ples randomised to the same arm will be offset by the
gain in precision from multiples randomised to the op-
posite arm, hence there will be a negligible impact on
power.
Intervention allocation
Treatment allocation of ibuprofen or placebo will be in a
ratio of 1:1 and masked such that the allocation will not
be known by clinicians, the baby’s family or the trial out-
come assessors.
Randomisation will be managed via a secure web-
based randomisation facility hosted by the NPEU Clin-
ical Trials Unit (CTU) with telephone back-up available
at all times (24/7, 365 days a year). The randomisation
programme will use a minimisation algorithm to ensure
balance between the groups with respect to the size of
the PDA (1.5 mm to < 2.0 mm; 2.0 mm to < 3.0 mm; ≥
3.0 mm), gestational age at birth (23 to 23+6 weeks; 24
to 24+6 weeks; 25 to 25+6 weeks; 26 to 26+6 weeks; 27
to 27+6 weeks; 28 to 28+6 weeks), age at randomisation
(< 12 h; 12 to < 24 h; 24 to < 48 h; 48 to < 72 h), sex
(male; female or indeterminate), trial site, multiple
births, mode of respiratory support at randomisation
((1) invasive ventilation (by an endotracheal tube); or
(2) non-invasive respiratory support through, nasal
CPAP, nasal ventilation, humidified high flow nasal
cannula therapy or, low flow oxygen ≥ 1.1 L/min; or (3)
receiving no mechanical ventilation, or pressure sup-
port (in room air, or low flow oxygen < 1.1 L/min, or
ambient oxygen)), and receiving inotropes or not at the
time of randomisation. Babies of multiple births will be
randomised individually.
The Senior Trials Programmer at the NPEU CTU will
write the randomisation programme and hold the treat-
ment allocation codes. If necessary, the code may be
broken for a single baby at the request of the site princi-
pal investigator (PI) or clinician in charge of the baby.
Data collection schedule
Data will be collected using paper case report forms
(CRFs) at the centres and entered into the study’s Open-
Clinica electronic database by NPEU CTU staff.
The CRFs to be completed are as follows:
Form 1: Trial entry
Form 2: Trial medication
Form 3: ECHO results
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Form 4: 36-week form
Form 5: Open-label treatment of PDA
Form 6: Baby outcomes
Form 6a: Necrotising enterocolitis report form
Form 7: Baby withdrawal form
Form 8a: SAE report form
Form 8b: SAE assessment form
Form 8c: SAE processing form
Form 9a: Incident and deviation form
Form 9b: Incident deviation and serious breach form
Additionally, a 2-year follow-up questionnaire will be
sent to parents of participating infants when they reach
2 years of age. These will be completed by the parents,
either on the paper questionnaire or an online form,
followed by data entry into the study’s OpenClinica
database by NPEU CTU staff, where necessary.
Table 3 summarises the schedule of data collection
and trial assessments.
Interim analyses and stopping rules
A Data Monitoring Committee (DMC), independent
of the applicants and of the Trial Steering Committee
(TSC), will review the progress of the trial at least an-
nually and provide advice on the conduct of the trial
to the TSC and (via the TSC) to the HTA. The com-
mittee will periodically review trial progress and
Table 2 Sample size required by event rates
Control group event
rate






Approximate total sample size
required
60% 47% 13% 22% 620
60% 48% 12% 20% 730
60% 49% 11% 18% 870
Fig. 2 Sample size per arm
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outcomes as well as secondary outcomes (e.g. death,
severe IVH).
Interim analyses will be supplied, in strict confi-
dence, to the DMC, as frequently as the Chair re-
quests. The DMC will aim to meet in person at least
annually, or more often as appropriate. At the request
of the DMC, interim meetings, in person or by tele-
conference, will be organised. Major trial issues may
need to be dealt with between meetings, by phone or
by email.
The DMC will be blinded to treatment allocations.
The trial statistician will bring a sealed envelope con-
taining the treatment allocations (provided by Head of
Trials Programming) that can be opened to break the
blind, if considered necessary.
In the light of interim data and other evidence from
relevant studies, the DMC will inform the TSC if, in
its view, there is proof beyond reasonable doubt that
the data indicate that the trial should be terminated.
A decision to inform the TSC of such a finding will
in part be based on statistical considerations. Appro-
priate proof beyond reasonable doubt cannot be spe-
cified precisely. A difference of at least 3 standard
errors in the interim analysis of a major endpoint
may be needed to justify halting or modifying the
study prematurely.
Trial reporting
The trial will be reported according to the principles of
the CONSORT statement [8]. Analysis of the short-term
health outcomes will be conducted after follow-up to
discharge has been completed for the last baby to be
discharged.
Protocol non-compliances
A protocol non-compliance is defined as a failure to ad-
here to the protocol such as the wrong intervention be-
ing administered, incorrect data being collected and
documented, errors in applying inclusion/exclusion cri-
teria or missed follow-up visits due to error.
All protocol non-compliances will be listed in the final
report. Non-compliances are defined below.
Major
The following are pre-defined major protocol non-
compliances with a direct bearing on the primary
outcome:
Data considered to be fraudulent
Minor
The following will be defined as minor protocol non-
compliances:
Table 3 Trial assessments
Procedure Baby hospitalisation
Screeninga Trial entry and treatment
(days 1−3)





















Oxygen reduction test ✓
SAEsd ✓ ✓
Concomitant medicatione ✓ ✓ ✓ ✓ ✓
aScreening assessments to be completed sufficiently in advance to enable randomisation and dosing within 72 h of birth. If consent cannot be obtained before
echocardiographic evaluation for eligibility, echocardiographic assessment should continue, and consent obtained when possible if a baby is deemed eligible
bRandomisation to be completed sufficiently in advance to enable dosing within 72 h of birth
cInitial trial drug administrations to be given soon after randomisation, after 6 h of age and within 72 h of birth. Subsequent doses to be administered 24 h after
the initial dose
dOnly adverse events which are serious will be recorded from first dose until 7 days after trial medication. Only unforeseeable SAEs will be reported
eConcomitant medications to be recorded only in relation to unforeseeable SAEs. In the event of an unforeseeable SAE all concomitant medication, including
medication given to the baby’s mother, 7 days prior to the onset of the event to the time of its resolution must be recorded on the SAE form
fAn echocardiogram scan will be performed when the baby reaches around 3 weeks of age (range of 18–24 days) or at hospital discharge if discharged earlier
gDemography and medications will be assessed through the PARCA-R and other questionnaires
hIf a baby transfers from the recruiting site to a continuing care site for on-going care details of any scan would be helpful
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Participants randomised in error These include
infants:
Who are < 23 weeks or ≥ 29 weeks of gestation
Who are ≥ 72 h old
With a PDA < 1.5mm in diameter OR who does not
have unrestrictive pulsatile left to right flow or,
growing pattern with right to left flow of 30% or more
Who have clinical or echocardiography evidence of
pulmonary hypertension
Where written informed consent has not been
obtained from the parent(s)
With a severe congenital anomaly
With contraindications to the use of ibuprofen
Who have had indomethacin, ibuprofen, or
paracetamol administered after birth
Treatment non-compliances
These include infants who:
Do not receive the allocated intervention. These
include infants who were allocated ibuprofen, and
instead received placebo, and vice versa.
Do not receive the correct number of doses. These
include infants who received less than 3 doses of the
trial medication.
Do not receive medication at the correct time.
These include infants who received their first dose
later than 72 h after birth, or received their 2nd or
3rd dose outside the specified dosing window (< 18 h
or > 72 h between doses 1 and 2, or doses 2 and 3;
or dose 3 completed > 7 days after first dose
administered).
Received open-label treatment without meeting the
criteria. These include infants who received open-
label treatment but did not meet the defined criteria
for doing so:
1. Inability to wean on ventilator (ventilated for at
least 7 days continuously) and any of inability to
wean oxygen; persistent hypotension; pulmonary
haemorrhage; signs of cardiac failure,
AND
2. Echocardiographic findings of a large PDA (PDA
≥2.0 mm with pulsatile flow)
AND
3. Echocardiographic findings of hyperdynamic
circulation or ductal steal.
Trial procedure non-compliances
ECHO not done around 3 weeks (18–24 days) of age
Oxygen reduction test not done when baby was
eligible




Exclusions to the analysis post-randomisation are de-
fined as any of the following:
Infants for whom a written consent form from the
parent(s) was not received
Infants for whom consent to use their data was
withdrawn by the parent(s)
Infants for whom an entire record of fraudulent data
was detected (should fraudulent data be detected,
consideration will be given to excluding all data for
the site where such data were found).
Population definitions
Intention to treat population The intention to treat
(ITT) population will be all infants randomised, exclud-
ing post-randomisation exclusions.
Interim analysis population Different denominators
will be used in the interim analysis:
Baseline data will be reported for all trial
participants with available data, excluding known
post-randomisation exclusions.
Outcome data will be reported for babies who can
be described as ‘completers’, i.e. all trial participants
with available data who have died or been
discharged home, excluding post-randomisation
exclusions.
Process outcomes will be reported for all trial
participants with available data, excluding known
post-randomisation exclusions.
Safety data will be reported for all trial participants
who received at least one dose of the study drug.
Safety population All infants randomised who received
at least one dose of the study drug.
Descriptive analyses
Representativeness of trial population and participant
throughput
The flow of participants through each stage of the trial
will be summarised by randomised group using a figure
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Included in safety population
Post-randomisation exclusions (with reasons)
Included in the ITT population
Baseline comparability of randomised groups
Baseline demographic and clinical characteristics at trial
entry will be described for all infants and their mothers
in the ITT population by randomised group. The follow-





Antenatal steroid use (any)
< 24 h before birth
≥ 24 h before birth
Antenatal COX inhibitor use
Antenatal magnesium sulphate use for
neuroprotection
Infant’s characteristics at trial entry
Enrolling centre
Born in enrolling centre
Postnatal age at randomisation (hours)
Gestational age at birth (weeks)
Mode of delivery
Forceps or Ventouse used in delivery
Main cause of preterm birth
Birth weight (g)
Birth weight z score
Head circumference (cm)
Head circumference z score
Sex
Baby is one of a multiple pregnancy
Sibling enrolled in the study (in multiple
pregnancies)
APGAR score 5 min after birth
Baby’s worst base excess at first hour after birth
CRIB II (without temperature) [9]
Size of PDA
Mode of respiratory support at randomisation
Receiving inotropes at randomisation
The number and percentage will be presented for bin-
ary and categorical variables. The mean and standard de-
viation or the median and the interquartile range will be
presented for continuous variables, and the range if ap-
propriate. There will be no tests of statistical significance
performed nor confidence intervals calculated for differ-
ences between randomised groups on any baseline
variable.
Losses to follow-up
Minimal loss to follow-up is expected for the primary
outcome since it is a short-term outcome and recorded
whilst the baby is in hospital.
Comparative analyses
Infants will be analysed according to their allocation, re-
gardless of the intervention they received (ITT popula-
tion). The placebo group will be used as the reference
group in all analyses.
Outcomes will be summarised with counts and per-
centages for categorical variables, means and standard
deviations for normally distributed continuous variables,
or median and interquartile range for other non-
normally distributed continuous or time-to-event
variables.
For binary outcomes, risk ratios and confidence inter-
vals will be calculated using log binomial regression, and
if a model fails to converge a Poisson regression model
with a robust variance estimator will be used. Continu-
ous outcomes will be analysed using linear regression
models, with mean differences and confidence intervals
presented for approximately normally distributed out-
comes. Skewed continuous outcomes will be analysed
using quantile regression models, with median differ-
ences and confidence intervals presented. Time-to-event
outcomes will be analysed using Cox regression and haz-
ard ratios with confidence intervals will be presented.
Analyses will be adjusted for all minimisation factors
where technically possible. Centre will be treated as a
random effect in the models, and all other factors as
fixed effects, including multiple births. Correlation be-
tween siblings from multiple births will be accounted for
in the adjusted model by nesting ‘multiple’ cluster as a
random effect within centre. All factors will be fitted as
fixed effects in quantile regression, as random effects
cannot be modelled using these methods of analysis.
Both crude and adjusted effect estimates will be pre-
sented, but the primary inference will be based on the
adjusted estimates.
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Analysis of secondary outcomes will be clearly delin-
eated from the primary outcomes in any statistical re-
ports produced.
Detailed definition of outcomes
The detailed derivations of each level of BPD are set out
in the Statistical Analysis Plan (Appendix B). Detailed
derivations for all other outcomes are described in a sep-
arate document.
Primary analysis
The primary analysis for the primary outcome and all
secondary outcomes will be conducted on the modified
ITT population, only excluding infants from the analysis
of an outcome if their data is missing for that outcome.
Minimisation factors will be adjusted for where technic-
ally possible, as described above.
Secondary analyses
A restricted analysis on the primary outcome and its
components, excluding infants who received open-label
treatment without meeting the specified criteria.
Pre-specified subgroup analyses
Pre-specified subgroup analyses will use the statistical
test of interaction and where appropriate, results will be
presented as risk ratios with confidence intervals. We
appreciate that the trial is not powered to examine tests
of interaction, and therefore interpretations of these will
be cautious.
Pre-specified subgroup analyses on the primary out-
come and its components will be based on:
gestational age at birth (23 to 23+6 weeks; 24 to 24+6
weeks; 25 to 25+6 weeks; 26 to 26+6 weeks; 27 to
27+6 weeks; 28 to 28+6 weeks)
size of the PDA (1.5 mm to < 2.0 mm; 2.0 mm to <
3.0 mm; ≥ 3.0 mm)
mode of respiratory support at randomisation
(invasive ventilation (by an endotracheal tube); non-
invasive respiratory support through nasal CPAP,
nasal ventilation, humidified high flow nasal cannula
therapy or, low flow oxygen ≥ 1.1 L/min; or receiv-
ing no mechanical ventilation, or pressure support
(in room air, or low flow oxygen < 1.1 L/min, or am-
bient oxygen)).
A further pre-specified subgroup analysis on NEC Bell
stage II and above will be conducted by size of the PDA.
Sensitivity analyses
No sensitivity analyses have been specified.
Significance levels and adjustment of p-values for
multiplicity
95% confidence intervals will be used for all pre-
specified outcome comparisons, including subgroup ana-
lyses. Due to the large number of secondary outcomes, a
subset of outcomes has been pre-specified on which
statistical inferences will be made (see Secondary short-
term outcomes above).
Missing data
Missing data will be described, for example, by pre-
senting the number of individuals in the missing cat-
egory. Missing data as a result of babies being lost to
follow-up is expected to be minimal for short-term
outcomes.
Statistical software employed
The statistical software Stata/SE will be used for all
analyses.
Safety data analysis
Serious adverse events (SAEs) will be listed by
allocation.
In addition, the following foreseeable SAEs occurring
within seven days after trial medication is completed will
be reported by trial arm:
Anaemia requiring transfusion
Clinically significant intracranial abnormality on
cranial ultrasound scan—intracranial haemorrhage
or white matter injury
Coagulopathy requiring treatment
Culture proven sepsis










Hypotension treated with inotropes
Impaired renal function (urine output < 0.5 ml/kg/h,
and or serum creatinine > 100 μmol/L)
Low serum sodium level/hyponatraemia (defined as
sodium < 130 mmol/L)
Necrotising enterocolitis
Neutropenia (defined as < 1.0 mmol/L)
Pneumothorax requiring treatment
Pulmonary hypertension requiring treatment with
pulmonary vasodilator
Respiratory failure






Any analyses not specified in the analysis protocol will
be exploratory in nature and will be documented in a
separate statistical analysis plan. Any post hoc analysis
requested by the oversight committees, a journal editor
or referees will be labelled explicitly as such.
Deviation from analysis described in protocol
None yet.
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